(688373)"SHANGHAI MICURX PHARMACEUTICAL CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 688373 · · 12 pages · Chinese
Summary by 6ix AI
The report indicates that the company experienced a decline in net profit and total profit compared to the previous year. Additionally, the report highlights a significant reduction in research and development expenditures during the quarter. The total assets of the company have decreased compared to the end of the previous year, reflecting ongoing financial challenges.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Shanghai MicuRx Pharmaceutical Co., Ltd. on 6ix
Earlier from Shanghai MicuRx Pharmaceutical
- (688373)"SHANGHAI MICURX PHARMACEUTICAL CO., LTD."Announcement on Signing of Authorization and License Agreement with ClearideBio
- (688373)"SHANGHAI MICURX PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 30th Meeting of the 2nd Board of Directors
- Announcement on Progress of Litigation Involving a U.S. Subsidiary
- Announcement on Shareholding Reduction Plan of Shareholder
- Announcement on Expiration of Shareholding Reduction Plan by Shareholder and Results of Shareholding Reduction
Later from Shanghai MicuRx Pharmaceutical
All Shanghai MicuRx Pharmaceutical news releasesFollow Shanghai MicuRx Pharmaceutical into a list and get an email when it puts out news.
Follow Shanghai MicuRx Pharmaceutical